Latest News and Press Releases

EDMONTON, Alberta, Sept. 08, 2021 (GLOBE NEWSWIRE) -- Ceapro Inc. (TSX-V: CZO; OTCQX: CRPOF) (“Ceapro” or the “Company”), a growth-stage biotechnology company focused on the development and...

– Company continues to increase R&D activities to advance clinical and preclinical programs – – Second quarter sales of $4,409,000 compared to $4,666,000 for second quarter 2020 – – Cash...

– Research focused on addressing root cause of disease and tissue damage for diseases such as COVID-19 – – Leveraging the unique expertise and methods developed by the Angiogenesis Foundation to...

- Second human trial to be conducted as part of a long-term Master Service Agreement with MHI- Phase 1 study with Ceapro’s pharmaceutical grade avenanthramide to be coordinated by MHI’s Montreal...

EDMONTON, Alberta, June 01, 2021 (GLOBE NEWSWIRE) -- Ceapro Inc. (TSX-V: CZO; OTCQX: CRPOF) (“Ceapro” or the “Company”), a growth-stage biotechnology company focused on the development and...

– Clinical study evaluating the well-known health claims of beta glucan and its potentially beneficial approach for patients to lower plasma cholesterol – – Study conducted in collaboration with the...

– Maintained production operations during COVID-19 pandemic, providing customers essential products while ensuring the health and safety of Company’s employees – – Increased R&D investments...

Maintained production operations during COVID-19 pandemic, providing customers with essential products and completing integration of manufacturing site, while ensuring the health and safety of...

– Project significantly advances broadening the application and utility of Ceapro’s proprietary, first-in-class technologies to develop innovative delivery systems composed of new chemical complexes –...

EDMONTON, Alberta, March 03, 2021 (GLOBE NEWSWIRE) -- Ceapro Inc. (TSX-V: CZO; OTCQX: CRPOF) (“Ceapro” or the “Company”), a growth-stage biotechnology company focused on the development and...